dnp nh peg2 c2 acid

DNP-NH-PEG2-C2-acid is a PEG-based linker for PROTACs, which connects two essential ligands critical for PROTAC molecule formation, enabling selective protein degradation through the ubiquitin-proteasome system within cells.

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

NH2-C2-NH-Boc (PROTAC Linker 22), an alkyl chain-based PROTAC linker, can be used in the synthesis of PROTACs.

1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker used in the synthesis of MT802 and SJF620, which are potent PROTAC BTK degraders with DC50s of 1 nM and 7.9 nM, respectively [1].

5-Ethynyl-2'-deoxyuridine (EdU) is a nucleoside analog of thymidine used to monitor de novo DNA synthesis through click chemistry and serves as an alkyl chain-based PROTAC linker for synthesizing PROTACs.

Pomalidomide-C2-acid is a PROTAC building block.

2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker utilized in PROTAC synthesis.

Cbz-NH-PEG12-C2-acid is a PEG-based linker for PROTACs, facilitating the connection of two essential ligands to form PROTAC molecules, thereby enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.

Cbz-NH-PEG2-CH2COOH is a PEG-based PROTAC linker [PROTACs] useful in PROTAC synthesis.

PROTAC ERRα ligand 2 is an inverse agonist for the estrogen-related receptor α (ERRα) with an IC50 of 5.67 nM.

TSPO ligand-2 (Carbonic acid) is a ligand of AUTAC1 which contains a p-fluorobenzylguanine and a Fumagillol moiety.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Fmoc-NH-PEG10-acid, a PEG-based PROTAC linker, is utilized in the synthesis of PROTACs.

Mal-PEG2-C2-Boc (Mal-PEG2-T-Butyl Ester) is a PEG-based PROTAC linker. Mal-PEG2-C2-Boc can be used in the synthesis of PROTACs.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Hydroxy-PEG4-(CH2)2-Boc is an uncleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs) and can also be employed in the synthesis of PROTAC.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and FGF21-receptor agonist, suitable for development as a potential treatment for T2DM.

Boc-NH-C4-acid is a PROTAC linker of the Alkyl ether class, utilized in the synthesis of PROTAC1 for the degradation of EED, EZH2, and SUZ12 in [PRC2].

Bromo-PEG3-C2-acid, a PEG-based PROTAC linker, can be utilized in PROTAC synthesis[1].

Compound 72-1, also known as BCL-xL BCL-2 ligand 1, serves as a ligand for BCL-xL and BCL-2 proteins. It can be tethered to an E3 ligase via a linker, facilitating the formation of PROTACs [1] [2].

VEGFR-2-IN-39 (PROTAC-5), a PROTAC that targets VEGFR-2 with an IC 50 of 208.6 nM, demonstrates low toxicity. It effectively inhibits the proliferation of EA.hy926, a type of HUVEC, in a concentration-dependent manner, achieving an IC 50 value of 38.65 µM [1].

PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a Bcl-2 family member), demonstrating an IC 50 of 0.6 nM.

PROTAC EGFR degrader 2 is a potent compound with an IC50 of 4.0 nM, demonstrating strong antiproliferative activity, and a DC50 of 36.51 nM, indicating robust EGFR degradation activity. It is suitable for synthesizing nitroreductase (NTR)-responsive PROTACs [1].

(R)-Azetidine-2-carboxylic acid, with catalog number T66331 and CAS number 7729-30-8, is a valuable organic compound for life sciences research.

Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

Thiol-PEG2-acid is a PEG derivative containing a thiol group and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond.

Bis (2-bromoethyl) ether, an alkyl chain-derived PROTAC linker, facilitates the synthesis of PROTACs.

Br-PEG6-C2-acid, a PEG-based linker for PROTACs, connects two essential ligands, facilitating the formation of PROTAC molecules and enabling selective protein degradation via the ubiquitin-proteasome system within cells.

Benzyl-PEG2-acid, a PEG-based linker for PROTACs, joins two essential ligands crucial for forming PROTAC molecules and enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

GID4 Ligand 2 (compound 67) is a selective binder for GID4 with an IC50 of 18.9 μM and a Kd of 17 μM, and can be used for the synthesis of PROTACs [1].

N-(Azido-PEG2)-N-Boc-PEG4-acid is a polyethylene glycol (PEG)-based linker developed for synthesizing PROteolysis TArgeting Chimeras (PROTACs)[1].

S-Acetyl-PEG3-C2-acid is a PEG-based linker for PROTACs that joins two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

N-Mal-N-bis(PEG2-acid) is a PEG-based linker used in PROTACs to join two essential ligands, facilitating selective protein degradation through the ubiquitin-proteasome system in cells.

endo-BCN-PEG2-C2-NHS ester is a PEG-based linker for PROTACs that connects two critical ligands, essential for the formation of PROTAC molecules, enabling selective protein degradation via the ubiquitin-proteasome system within cells.

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Tos-PEG2-C2-Boc is a PEG-based linker for PROTACs, facilitating the selective degradation of proteins by connecting two essential ligands through the ubiquitin-proteasome system within cells.

DBCO-PEG2-NH-Boc is a PEG-based linker for PROTACs that connects two essential ligands, facilitating the formation of PROTAC molecules and enabling selective protein degradation through the ubiquitin-proteasome system within cells.

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

Cbz-NH-PEG6-C2-acid [CB92080147] is a PEG-based linker for PROTACs that joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

N-Mal-N-bis(PEG2-C2-Boc) is a polyethylene glycol (PEG)-based linker used in proteolysis targeting chimeras (PROTACs)[1].

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker used in antibody-drug conjugation (ADC) to connect antibodies with drugs.

NH-bis(PEG2-C2-Boc) is an alkyl ether-based linker used in the synthesis of PROTACs [1].

Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a novel synthesized conjugate compound functioning as an E3 ligase ligand-linker in PROTAC technology. Incorporating a Pomalidomide-derived cereblon ligand that selectively binds to the E3 ligase cereblon and a 2-unit PEG linker, it provides stability and flexibility to the conjugate.

Mal-NH-ethyl-SS-propionic acid, a cleavable linker employed for the synthesis of antibody-drug conjugates (ADCs)[1], plays a crucial role in the modulation of drug release from the conjugate.

Mal-amido-PEG8-C2-acid (US2018339985, example 142) is a noncleavable linker for antibody-drug conjugates (ADCs) [1].